With over 1,000 participants, nearly 600 poster submissions, and 27 conference supporters, the 2013 CCRC concluded on November 6th to wide acclaim. The scientific program, which spanned the cancer research spectrum, was well-received - in fact, 90% of evaluation respondents reported being satisfied/very satisfied with the quality of the plenary sessions and symposia. The Careers in Cancer Research Development Program, hosted by the CIHR Institute of Cancer Research and the Canadian Cancer Society Research Institute, was interwoven throughout the conference and provided useful information and resources for the new generation of cancer researchers. The next conference will be in 2015 so stay tuned for further announcements about this important Canadian science event.
The CCRA announced today the recipients of its biennial awards which recognize significant contributions to cancer research in Canada. Dr. Victor Ling receives the award for Exceptional Leadership in Cancer Research, Dr. John E. Dick receives the award for Outstanding Achievements in Cancer Research, and Mr. Bob McDonald receives the award for Distinguished Service to Cancer Research. The awards will be presented during the CCRA’s Canadian Cancer Research Conference in Toronto on November 5th, 2013. For more information, click here.
Our latest report updates our initial analysis released in 2009 and reveals that the level of growth in investment from 2005 to 2010 for research on childhood and adolescent cancers surpassed that found for cancer research overall. Furthermore, there was an influx of new researchers as well as trainees successfully competing for training awards. Investment in treatment and etiological research showed the greatest upward shifts over the six years, consistent with the trends found for the overall cancer research investment. The data suggests that survivorship research is an area of strength. To access this report, click here.
Dr. Jacques Magnan, currently the Senior Scientific Lead for the Canadian Partnership for Tomorrow Project at the Canadian Partnership Against Cancer, will assume the role of interim CCRA co-Chair effective July 1st, 2013. Dr. Magnan undertakes this leadership role with CCRA while Dr. Elizabeth Eisenhauer assumes an interim leadership role with Queen's University as Director of the NCIC Clinical Trials Group until such time as a new permanent director is recruited. Dr. Eisenhauer will continue to support the development of the Canadian Cancer Clinical Trials Network.
We welcome Dr. Magnan in this new capacity and look forward to working with him.